TechConnect Innovation Program

Therapeutic applications of Cerium Oxide nanoparticles in treatment of polymicrobial sepsis induced multi-organ dysfunction syndrome

Marshall University Research Corporation - Technology Transfer Office, West Virginia, United States

TECHNOLOGY SUMMARY

Injection of cerium oxide nanoparticles can be used as a medication to prevent and treat sepsis, acute kidney, liver injury and associated inflammatory diseases in human and all types of animals.

Primary Application Area: Pharmaceuticals & Personal Care

Technology Development Status: Prototype

Technology Readiness Level: TRL 4

FIGURES OF MERIT

Value Proposition: Sepsis is the 10th leading cause of death among hospitalized patients. Unpredictable, progresses rapidly, with costs exceeding $17 billion annually. No current FDA approved treatment. Administered once intravenously, requires no antibiotics, fluid resuscitation, vasopressors or other supportive care. Shelf stable in powder or liquid form at almost any temperature indefinitely.

SHOWCASE SUMMARY

Organization Type: Academic/Gov Lab

Showcase Booth #: 619

Website: www.marshall.edu/tto

GOVT/EXTERNAL FUNDING SOURCES

Government Funding/Support to Date: The Center for Diagnostic Nanosystems was formally established in September of 2010 with funds from the U.S. Department of Energy award #DE-SC0005162, Project $4,765,715.00. The objective of the Center is to develop new ways to diagnose, monitor and treat chronic diseases. In particular we are interested in helping to devise new technologies for the treatment of cardiovascular disease, metabolic syndrome, cancer and Alzheimer's disease.

Primary Sources of Funding: Federal Grant, University

Looking for: Both Funding and Development Partners